Cargando…

Clinical features and outcomes of 25 patients with primary adenosquamous cell carcinoma of the prostate

The aim of the present study was to examine the epidemiology, natural history, treatment and long-term survival of patients with adenosquamous cell carcinoma of the prostate. The Surveillance, Epidemiology, and End Results (SEER) Program database was used to identify ASCC of prostate cases between J...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jue, Wang, Fen Wei, LaGrange, Chad A, Hemstreet, George P
Formato: Texto
Lenguaje:English
Publicado: PagePress 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2994527/
https://www.ncbi.nlm.nih.gov/pubmed/21139962
http://dx.doi.org/10.4081/rt.2010.e47
_version_ 1782192959709511680
author Wang, Jue
Wang, Fen Wei
LaGrange, Chad A
Hemstreet, George P
author_facet Wang, Jue
Wang, Fen Wei
LaGrange, Chad A
Hemstreet, George P
author_sort Wang, Jue
collection PubMed
description The aim of the present study was to examine the epidemiology, natural history, treatment and long-term survival of patients with adenosquamous cell carcinoma of the prostate. The Surveillance, Epidemiology, and End Results (SEER) Program database was used to identify ASCC of prostate cases between January 1973 and December 2006. Survival probabilities were estimated using the Kaplan-Meier methods and compared using the log-rank test. A total of 25 patients with adenosquamous cell carcinoma of the prostate were identified during the study period. The median age was 74 years (range 53–98). Twenty percent of study subjects presented with metastatic disease. Among those patients with known grade (n=16), 75% had poorly or undifferentiated histology. A total of 40% of study subjects received radical prostatectomy, while 24% of the patients had primary radiation therapy. The 1-, 3-, and 5-year cancer specific survival rates for the entire cohort were 55.2%, 37.8%, and 30.3%, respectively. For patients who underwent prostatectomy, the 1-, 3-, and 5-year survival rates were 78%, 78%, and 63%, respectively. For the patients who did not receive prostatectomy, the 1-year survival rates were 38.7% and none survived to three years. Adenosquamous cell carcinoma is a rare aggressive subtype of prostate cancer with poor cancer specific survival. The development of new therapeutic approaches for this aggressive tumor is urgently needed.
format Text
id pubmed-2994527
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher PagePress
record_format MEDLINE/PubMed
spelling pubmed-29945272010-12-07 Clinical features and outcomes of 25 patients with primary adenosquamous cell carcinoma of the prostate Wang, Jue Wang, Fen Wei LaGrange, Chad A Hemstreet, George P Rare Tumors Article The aim of the present study was to examine the epidemiology, natural history, treatment and long-term survival of patients with adenosquamous cell carcinoma of the prostate. The Surveillance, Epidemiology, and End Results (SEER) Program database was used to identify ASCC of prostate cases between January 1973 and December 2006. Survival probabilities were estimated using the Kaplan-Meier methods and compared using the log-rank test. A total of 25 patients with adenosquamous cell carcinoma of the prostate were identified during the study period. The median age was 74 years (range 53–98). Twenty percent of study subjects presented with metastatic disease. Among those patients with known grade (n=16), 75% had poorly or undifferentiated histology. A total of 40% of study subjects received radical prostatectomy, while 24% of the patients had primary radiation therapy. The 1-, 3-, and 5-year cancer specific survival rates for the entire cohort were 55.2%, 37.8%, and 30.3%, respectively. For patients who underwent prostatectomy, the 1-, 3-, and 5-year survival rates were 78%, 78%, and 63%, respectively. For the patients who did not receive prostatectomy, the 1-year survival rates were 38.7% and none survived to three years. Adenosquamous cell carcinoma is a rare aggressive subtype of prostate cancer with poor cancer specific survival. The development of new therapeutic approaches for this aggressive tumor is urgently needed. PagePress 2010-09-30 /pmc/articles/PMC2994527/ /pubmed/21139962 http://dx.doi.org/10.4081/rt.2010.e47 Text en ©Copyright J. Wang et al., 2010 This work is licensed under a Creative Commons Attribution 3.0 License (by-nc 3.0). Licensee PAGEPress, Italy
spellingShingle Article
Wang, Jue
Wang, Fen Wei
LaGrange, Chad A
Hemstreet, George P
Clinical features and outcomes of 25 patients with primary adenosquamous cell carcinoma of the prostate
title Clinical features and outcomes of 25 patients with primary adenosquamous cell carcinoma of the prostate
title_full Clinical features and outcomes of 25 patients with primary adenosquamous cell carcinoma of the prostate
title_fullStr Clinical features and outcomes of 25 patients with primary adenosquamous cell carcinoma of the prostate
title_full_unstemmed Clinical features and outcomes of 25 patients with primary adenosquamous cell carcinoma of the prostate
title_short Clinical features and outcomes of 25 patients with primary adenosquamous cell carcinoma of the prostate
title_sort clinical features and outcomes of 25 patients with primary adenosquamous cell carcinoma of the prostate
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2994527/
https://www.ncbi.nlm.nih.gov/pubmed/21139962
http://dx.doi.org/10.4081/rt.2010.e47
work_keys_str_mv AT wangjue clinicalfeaturesandoutcomesof25patientswithprimaryadenosquamouscellcarcinomaoftheprostate
AT wangfenwei clinicalfeaturesandoutcomesof25patientswithprimaryadenosquamouscellcarcinomaoftheprostate
AT lagrangechada clinicalfeaturesandoutcomesof25patientswithprimaryadenosquamouscellcarcinomaoftheprostate
AT hemstreetgeorgep clinicalfeaturesandoutcomesof25patientswithprimaryadenosquamouscellcarcinomaoftheprostate